Page 16 - Samsung Bioepis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Merck s Keytruda tops drug sales in Korea

Merck’s immuno-oncology drug Keytruda, one of the best-selling drugs in the world, topped drug sales in Korea for the second consecutive year in 2023, according to market tracker IQVIA on Tuesday. Keytruda’s sales in Korea came to some 399 billion won ($300 million) in 2023, up 159 billion won from the previous year, while global sales of Keytruda hit $25 billion, making it the top-selling drug worldwide..

South koreaChong kun dangSamsung bioepisDrug administrationKun dangThe korea heraldOrean newsOuth korea newsOuth korea news in englishSia newsK pop코리아 헤럴드

Samsung Bioepis Wins Order for Hadlima From US Government

EconoTimes is a fast growing non-partisan source of news and intelligence on global economy and financial markets, providing timely, relevant, and critical insights for market professionals and those who want to make informed investment decisions.

South koreaUnited statesSoult ukpyolsiNorth chicagoSouth koreanSamsung bioepiSamsung bioepisKevin aliMinistry of veterans affairsSamsung bioepis coDepartment of veterans affairsUs department of veterans affairsVeterans affairsAbbvie incVie incKorea economic

For Retina Specialists, 2024 Is a Time to Try New Tools

This is a year for ophthalmologists to get acclimated with three blockbuster retina drugs approved in 2023, get reacclimated with a returning implant, and to brace for 2025 and beyond.

United statesWest virginiaIveric bioAbbvie allerganGenentech rochePegcetacoplan syfovreReginal sandersSamsung bioepisDavid boyerLos angelesRetina societyJanssen pharmaceuticalsAmerican society of retina specialistDrug administrationEyepoint pharmaceuticalsRegeneron pharmaceuticals

US Veterans Affairs to replace Humira with biosimilar on national formulary

US Veterans Affairs to replace Humira with biosimilar on national formulary
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

United statesShenaz baghaKevin alisaidPushtouch autoinjectorSamsung bioepisUs department of veterans affairsUs veterans affairsVeterans affairs

Updates On Aflibercept BPCIA Litigation - Life Sciences, Biotechnology & Nanotechnology

On Friday, January 20, 2024, Regeneron Pharmaceuticals, Inc. ("Regeneron") filed an ex parte application for a scheduling order setting the schedule for preliminary injunction proceedings or, in the alternative, an emergency status conference.

United statesNorthern districtWest virginiaSamsung bioepisCelltrion incRegeneron pharmaceuticals incAmgen incJudicial panelUs district courtSamsung bioepis coJudicial panel on multidistrictMylan pharmaceuticals incBiocon biologics incRegeneron pharmaceuticalsCentral districtChief judge kleeh